Clinical Trials Sponsored by MSD Merck Sharp & Dohme AG

Total 3954 results

ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia
TME Pharma AG
Merck Sharp & Dohme LLC

Not yet recruiting

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (OPTIMUS)

Metastatic Pancreatic Cancer
TME Pharma AG
Merck Sharp & Dohme LLC

Completed

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (Keynote-559)

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer

Germany
Kelly, Maureen, M.D.
Merck Sharp & Dohme LLC

Unknown

A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs

Implantation, Embryo

United States
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer

United States, Israel, Taiwan
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Malaria
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Renal Impairment
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

Alzheimer's Disease

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Squamous Cell Carcinoma

Japan
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Taiwan, Israel, Argentina, Japan, Korea, Republic of, Turkey, Colombia, China, Mexico, Germany, Italy, South Africa, Spain
Merck Sharp & Dohme LLC

Recruiting

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

HIV-1 Infection

United States, Israel, Puerto Rico, Japan, South Africa, Chile, Thailand, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Kidney Failure, Chronic | End-Stage Renal Disease | End-Stage Kidney Disease

United States
Merck Sharp & Dohme LLC

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) (MOONBEAM)

Pulmonary Arterial Hypertension

Germany, United States, Poland, Spain, Colombia, France, Turkey, Israel, Australia, United Kingdom, Netherlands
Merck Sharp & Dohme LLC

Recruiting

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

Neoplasms | Advanced/Metastatic Solid Tumors

Canada, Israel, United States, Netherlands
Merck Sharp & Dohme LLC

Recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Korea, Republic of, Taiwan, Italy, France, Thailand, Turkey, Brazil, Switzerland, Singapore, Germany, Chile, Norway
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, China, Taiwan, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, Norway
Merck Sharp & Dohme LLC

Not yet recruiting

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

HIV | Human Immunodeficiency Virus
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Advanced Solid Tumors

China, United States, Australia, Canada, Chile, Israel, Japan, Korea, Republic of, Panama, Poland, Spain, Switzerland, Turkey, New Zealand, Taiwan
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Carcinoma, Hepatocellular | Colorectal Neoplasms | Esophageal Neoplasms | Endometrial Neoplasms | Pancreatic Ductal Adenocarcinoma | Biliary Tract Neoplasms

Israel, United States, Australia, Belgium, Chile, France, Korea, Republic of, Netherlands, Spain, New Zealand
Merck Sharp & Dohme LLC

Recruiting

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Colorectal Cancer

United States, Belgium, Canada, Germany, Italy, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, United Kingdom, France, Denmark, Romania, Estonia, Hungary, Guatemala, Costa Rica, Lithuania, Greece, Colombia, Netherl...
Merck Sharp & Dohme LLC

Recruiting

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Invasive Fungal Infection

Israel, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

Nosocomial Pneumonia

United States, Estonia, Greece, Spain, Ukraine, Chile, Russian Federation, Colombia
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) (PNEU-PED-KOR)

Pneumococcal Disease

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Breast Neoplasms | Colorectal Cancer | Metastatic HER2+ Advanced Breast Cancer | Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Neoplasms
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Carcinoma, Squamous Cell

Ukraine, United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Mexico, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Spain, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Dengue Virus | Dengue Disease

United States, Australia, Canada, Finland, Germany, Israel, Taiwan
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

End Stage Renal Disease | Renal Impairment

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Investigational Agents for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Small Cell Lung Carcinoma

Poland, Russian Federation, United States, Australia, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, New Zealand, Poland, Russian Federation, South Africa, Spain, Switzerland, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)

Neoplasms
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Neoplasms

Poland, United States, Australia, Canada, China, France, Greece, Israel, Japan, Korea, Republic of, South Africa, Spain
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) (DRIVE-FORWARD)

HIV-1
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

Schizophrenia

United States, Bulgaria, Croatia, Japan, Korea, Republic of, Latvia, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine
Merck Sharp & Dohme LLC

Completed

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019) (TQT)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Neoplasms

Italy, United States, Australia, Canada, Chile, Israel, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Belgium, Brazil, Canada, Chile, China, Estonia, France, Germany, Guatemala, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Philippines, Poland, Russian Federation, Singapore, Taiwan, Ukraine, United...
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

Pneumococcal Disease

United States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Merkel Cell Carcinoma

United States, Australia, Canada, France, Italy, New Zealand, Spain, Sweden
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Carcinoma, Renal Cell

United States, Australia, Belgium, Greece, Ireland, Israel, Netherlands, Russian Federation, United Kingdom
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension

Prostatic Neoplasms

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Advanced Non-Small Cell Lung Cancer

Poland, Russian Federation, United States, Australia, Canada, Hong Kong, Ireland, Italy, Japan, Korea, Republic of, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Head and Neck Neoplasms

United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Spain, Taiwan, Turkey, United Kingdom

Clinical Trials Sponsored by MSD Merck Sharp & Dohme AG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations